3M (MMM) Financial History
Review 3M annual and quarterly financial results, key ratios, insider transactions and SEC filing history in one chronological view. Data available from FY2007 through FY2025.
Financials
19 fiscal years, FY2007 to FY2025
Insider trades
368 trades
Risk factor changes
16 changes in the latest 10-K
Filings
Annual and quarterly reports
Compare
Side by side with another company
3M Financial Statements
History since FY2007. Annual, in US dollars. Source: 10-K XBRL data.
3M Revenue and Growth
Compare reported revenue and year-over-year revenue growth across available fiscal years.
3M Income Statements
Review revenue, gross profit, operating income, net income and earnings per share.
3M Balance Sheets
Review reported debt and book-value-based ratios where company data is available.
3M Cash Flow Statements
Compare reported free cash flow across the available fiscal history.
3M Financial Ratios
Compare net margin, price-to-earnings and price-to-book ratios by fiscal year.
| Fiscal year | FY2007 🔒 | FY2008 🔒 | FY2009 🔒 | FY2010 🔒 | FY2011 🔒 | FY2012 🔒 | FY2013 🔒 | FY2014 🔒 | FY2015 🔒 | FY2016 🔒 | FY2017 🔒 | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022Insiders net sold $7.7M | FY2023 | FY2024 | FY2025Insiders net sold $31.3M |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $35.4B | $26.2B | $24.6B | $24.6B | $24.9B |
| Revenue growth | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | — | -26.0% | -5.9% | -0.1% | +1.5% |
| Gross profit | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $16.6B | $10.3B | $9.6B | $10.1B | $10.0B |
| Operating income | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $7.4B | $4.4B | $-10.7B | $4.8B | $4.6B |
| Net income | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $5.9B | $5.8B | $-7.0B | $4.2B | $3.3B |
| Debt | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $17.5B | $16.0B | $16.1B | $13.1B | $12.6B |
| Free cash flow | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $5.9B | $3.8B | $5.1B | $0.6B | $1.4B |
| Net margin | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | 16.7% | 22.1% | -28.4% | 17.0% | 13.0% |
| EPS (diluted) | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $10.12 | $10.18 | $-12.63 | $7.55 | $6.00 |
| P/E ratio | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | 17.6× | 11.8× | n/m | 17.1× | 26.7× |
| P/B ratio | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | 6.8× | 4.5× | 12.6× | 18.1× | 18.1× |
Daily closing prices, aggregated by calendar year.
| Year | 2000 🔒 | 2001 🔒 | 2002 🔒 | 2003 🔒 | 2004 🔒 | 2005 🔒 | 2006 🔒 | 2007 🔒 | 2008 🔒 | 2009 🔒 | 2010 🔒 | 2011 🔒 | 2012 🔒 | 2013 🔒 | 2014 🔒 | 2015 🔒 | 2016 🔒 | 2017 🔒 | 2018 🔒 | 2019 🔒 | 2020 🔒 | 2021 🔒 | 2022 | 2023 | 2024 | 2025 | 2026 (YTD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Open | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $178.31 | $121.49 | $108.79 | $130.10 | $160.15 |
| Close | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $119.93 | $109.31 | $129.10 | $160.07 | $187.66 |
| High | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $181.77 | $129.76 | $141.30 | $174.61 | $198.13 |
| Low | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $107.09 | $85.34 | $88.29 | $122.69 | $139.38 |
| Annual return | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | -32.5% | -8.9% | +18.1% | +24.0% | +17.2% |
3M Insider Transactions
From Form 4 filings. Showing the latest 5 of 368 trades.
| Traded | Filed | Insider | Type | Shares | Value | % of holdings |
|---|---|---|---|---|---|---|
| 2026-10-30 | 2026-11-02 | Wyck Jonathan Van Executive VP Chief Strategy… | Option exercise (2 trades) | 3,002 | $262K | — |
| 2026-10-30 | 2026-11-02 | Wyck Jonathan Van Executive VP Chief Strategy… | Tax withholding | 460 | $80K | — |
| 2026-10-07 | 2026-10-09 | Kevin Rhodes Executive VP | Option exercise (2 trades) | 352 | $29K | — |
| 2026-10-07 | 2026-10-09 | Kevin Rhodes Executive VP | Tax withholding | 176 | $29K | — |
| 2026-10-07 | 2026-10-09 | Tushar Kshirsagar Executive VP Chief Tech Officer | Option exercise (2 trades) | 106 | $8,592 | — |
3M Risk Factor Changes
Latest 10-K compared with the year before. 16 changes found.
On April 1, 2024, the Company completed the planned spin-off of its health care business, which is known as Solventum Corporation, as an independent company.
The Company’s financial results depend on the successful execution of its business operating plans.
In the ordinary course of business, the Company relies on centralized and local information technology networks and systems, some of which are provided, hosted, or managed by vendors and other third parties, to proces…
Demand for the Company’s products, which impacts revenue and profit margins, is affected by, among other things: (i) the development and timing of the introduction of competitive products; (ii) the Company’s pricing s…
The Company has been voluntarily cooperating with various local, state, federal (primarily the U.S.
As also noted, 3M has been working to discontinue the use of PFAS across its product portfolio and has made substantial progress in eliminating such use in the Company's products.
3M announced in December 2022 it would take two further actions with respect to PFAS (2022 PFAS Announcement): exiting all PFAS manufacturing by the end of 2025, and working to discontinue the use of PFAS across its p…
As previously reported, governments in the United States and internationally have increasingly been regulating a broad group of perfluoroalkyl and polyfluoroalkyl substances, collectively known as “PFAS,” including so…
* The Company’s results are impacted by the effects of, and changes in, worldwide economic, political, regulatory, international trade, geopolitical, tariffs and retaliatory counter measures, and other external condit…
including the risk of legal claims or proceedings, investigations or enforcement actions by U.S., state, or foreign regulators; liabilities or penalties under applicable laws and regulations, including privacy laws an…
The Company or its third-party vendors may develop or incorporate artificial intelligence technology in certain business processes, services or products.
The global economy has been impacted by geopolitical tensions.
Artificial intelligence (AI) technologies support a range of the Company’s activities, including research and development, operational processes, customer facing tools, and other business functions.
*The Company’s use of artificial intelligence technologies exposes the Company to risks which could have a material adverse effect on the Company’s business, reputation and results of operations.
The Company is also subject to certain risks as a direct and indirect supplier to the U.S.
The global economy has been impacted by geopolitical tensions.
3M SEC Filings
Latest annual and quarterly reports, current reports, proxy statements and ownership filings.
| Form | Filed | Description | Document |
|---|---|---|---|
| Current report (8-K) | 2026-11-04 | Material agreement, Other news | View document |
| Quarterly report (10-Q) | 2026-10-20 | Quarter ended Sep 30, 2026 | View document |
| Current report (8-K) | 2026-10-20 | Quarterly results | View document |
| Current report (8-K) | 2026-10-19 | Company update | View document |
| Ownership change (13D/13G) amendment | 2026-10-16 | Large shareholder report (5% or more) | View document |
3M financial metrics by year
3M in the S&P 500 rankings
- #97 by operating income as of FY2025
S&P 500 is a trademark of S&P Dow Jones Indices LLC. StockYears is not affiliated with or endorsed by S&P Dow Jones Indices.
Compare 3M with similar companies
- MMM vs BAX Baxter International
- MMM vs BDX Becton Dickinson
- MMM vs BSX Boston Scientific
- MMM vs DXCM Dexcom
- MMM vs PODD Insulet
- MMM vs RMD ResMed
- MMM vs SOLV Solventum
- MMM vs SYK Stryker
- MMM vs WST West Pharmaceutical Services